Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Propanc Biopharma (PPCB) reported preclinical data for its PRP treatment in advanced pancreatic cancer, which has FDA Orphan Drug Designation. The company plans to begin a Phase 1b clinical trial in Q1 2027. PRP is still in early-stage development, and further regulatory approvals are required.

Propanc Biopharma (PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP also reduced metastasis, improved chemotherapy sensitivity, and extended survival. The company completed a 1-for-25 reverse stock split and shares surged 202.75% to $3.22.

Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.

Propanc Biopharma, Inc. (PPCB) shares rose about 26% after the company said it started a share repurchase program to buy a first tranche of up to $500,000 over 30 days. The stock was around $1.8150 on Nasdaq, up about 25.7% in the latest session.

Propanc Biopharma (PPCB) said its board approved a share repurchase program authorizing buybacks of up to $5.0 million of its common stock. The company expects the program to support shareholder ownership and improve per-share economics, citing management’s capital allocation approach. In pre-market trading, PPCB was at $2.87, up 114.23% on Nasdaq.

First Phosphate (NASDAQ:PHOS) plans to develop a phosphate mine in Quebec by 2029, targeting the LFP battery supply chain. The company aims to produce 900,000 metric tons of phosphate concentrate annually, supporting 50% of EV production in North America. The project has a CAD 2.1 billion net present value, 37.1% internal rate of return, and a 23-year mine life, according to the company. First Phosphate has secured government funding and partnerships for its development.